

Genomic And Proteomic Tool Market 2026 Precision Medicine Research Accelerating Adoption

*The Business Research Company's
Genomic And Proteomic Tool Market
2026 Precision Medicine Research
Accelerating Adoption*

LONDON, GREATER LONDON, UNITED KINGDOM, March 17, 2026

/EINPresswire.com/ -- "Genomic And Proteomic Tool market to surpass \$57 billion in 2030. In comparison, the Genomics market, which is considered as its parent market, is expected to be approximately \$108 billion by 2030,

with Genomic And Proteomic Tool to represent around 53% of the parent market. Within the broader Medical Equipment industry, which is expected to be \$1,218 billion by 2030, the Genomic And Proteomic Tool market is estimated to account for nearly 5% of the total market value.

“

Expected to grow to \$56.95 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%”


*The Business Research
Company*

Which Will Be The Biggest Region In The Genomic And Proteomic Tool Market in 2030

Asia-Pacific will be the largest region in the genomic and proteomic tool market in 2030, valued at \$20 billion. The market is expected to grow from \$11 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The rapid growth can be attributed to expanding government

funding for genomics research, increasing adoption of precision medicine initiatives, rising investments in next-generation sequencing and proteomics infrastructure, growing clinical research activities, and the presence of large patient populations supporting large-scale genomic studies across countries such as China, Japan, South Korea, and India.


Which Will Be The Largest Country In The Global Genomic And Proteomic Tool Market In 2030? The USA will be the largest country in the genomic and proteomic tool market in 2030, valued at



\$17 billion. The market is expected to grow from \$10 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to substantial federal funding for genomics and precision medicine initiatives, a strong presence of leading biotechnology and pharmaceutical companies, expanding clinical sequencing and molecular diagnostics applications, increasing adoption of advanced next-generation sequencing and mass spectrometry platforms, growth in multi-omics research programs, and continuous innovation in bioinformatics and AI-driven data analysis technologies across academic and commercial research institutions.

Request A Free Sample Of The Genomic And Proteomic Tool Market Report

https://www.thebusinessresearchcompany.com/sample_request?id=28235&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar PR



What Will Be The Largest Segment In The Genomic And Proteomic Tool Market In 2030?

The genomic and proteomic tool market is segmented by product type into reagents, instruments, software, and consumables. The reagents market will be the largest segment of the genomic and proteomic tool market segmented by product type, accounting for 44% or \$25 billion of the total in 2030. The reagents market will be supported by the increasing focus on neuroscience and cognitive research, rising demand for preclinical drug development studies, advancements in automated tracking and data analytics systems, growing adoption of AI-enabled behavioral monitoring platforms, expanding academic and pharmaceutical research funding, and stricter regulatory requirements emphasizing accurate and reproducible experimental outcomes. The recurring demand for sequencing kits, library preparation reagents, PCR and qPCR reagents, proteomics assay kits, and sample preparation solutions. The genomic and proteomic tool market is segmented by technology into sequencing; polymerase chain reaction (PCR), mass spectrometry (MS), microarrays, electrophoresis, chromatography, flow cytometry, and nucleic acid sample preparation. The genomic and proteomic tool market is segmented by sales channel into original equipment manufacturer (OEM), and aftermarket. The genomic and proteomic tool market is segmented by application into biomarker discovery, drug

discovery and development, molecular diagnostics, personalized medicine, gene expression analysis, epigenomics research, microbiome analysis, and vaccine development. The genomic and proteomic tool market is segmented by end user into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and other end-users.

The genomic and proteomic tool market is segmented by technology into sequencing; polymerase chain reaction (PCR), mass spectrometry (MS), microarrays, electrophoresis, chromatography, flow cytometry, and nucleic acid sample preparation.

The genomic and proteomic tool market is segmented by sales channel into original equipment manufacturer (OEM), and aftermarket.

The genomic and proteomic tool market is segmented by application into biomarker discovery, drug discovery and development, molecular diagnostics, personalized medicine, gene expression analysis, epigenomics research, microbiome analysis, and vaccine development.

The genomic and proteomic tool market is segmented by end user into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and other end-users.

What Is The Expected CAGR For The Genomic And Proteomic Tool Market Leading Up To 2030?
The expected CAGR for the genomic and proteomic tool market leading up to 2030 is 12%.

What Will Be The Growth Driving Factors In The Global Genomic And Proteomic Tool Market In The Forecast Period?

The rapid growth of the global genomic and proteomic tool market leading up to 2030 will be driven by the following key factors that are expected to reshape preclinical research methodologies, laboratory infrastructure standards, regulatory compliance frameworks, and innovation across global biomedical and life sciences ecosystems.

Rising Adoption Of Next-Generation Sequencing (NGS) - The rising adoption of next-generation sequencing (NGS) is expected to become a key growth driver for the genomic and proteomic tool market by 2030. The increasing adoption of next-generation sequencing (NGS) is significantly propelling the growth of the genomic and proteomic tools market by facilitating fast, high-throughput analysis of complex genetic and protein datasets. NGS delivers detailed insights into gene expression patterns, genetic variations, and protein interactions, thereby advancing applications in precision medicine, biomarker discovery, and disease diagnostics. Declining sequencing costs and enhanced processing speed have made large-scale genomic research more accessible to academic institutions, biotechnology firms, and healthcare providers. In addition, the widespread use of NGS stimulates demand for associated products and services, including library preparation kits, reagents, advanced analytical software, and bioinformatics platforms. Collectively, these factors are accelerating scientific innovation and broadening the integration of genomics and proteomics across clinical and research environments. As a result,

the rising adoption of next-generation sequencing (NGS) is anticipated to contributing to 2.2% annual growth in the market.

Increasing Demand For Personalized Medicine - The increasing demand for personalized medicine is expected to emerge as a major factor driving the expansion of the genomic and proteomic tool market by 2030. The growing emphasis on personalized medicine is accelerating the expansion of the genomic and proteomic tools market, as these technologies enable in-depth analysis of individual genetic variations and protein expression patterns. By detecting specific biomarkers, mutations, and molecular pathways, they support the customization of therapies based on a patient's distinct biological characteristics. This precision-driven approach enhances treatment effectiveness, reduces adverse effects, and improves diagnostic accuracy. Consequently, pharmaceutical companies and healthcare institutions are increasingly investing in advanced genomic and proteomic tools to advance targeted therapeutics and precision diagnostic solutions. Consequently, the increasing demand for personalized medicine is projected to contribute to around 1.7% annual growth in the market.

Expansion Of Drug Discovery And Development Activities - The expansion of drug discovery and development activities is expected to act as a key growth catalyst for the genomic and proteomic tool market by 2030. The growth of drug discovery and development activities is fueling the expansion of the genomic and proteomic tools market, as these technologies allow researchers to more effectively identify disease-associated genes, proteins, and molecular pathways. Genomic sequencing and proteomic profiling support the discovery of new therapeutic targets and provide deeper insights into drug mechanisms at the molecular level. As a result, pharmaceutical and biotechnology companies are increasingly leveraging these advanced tools to accelerate the development of personalized and targeted treatment strategies. Therefore, the expansion of drug discovery and development activities is projected to contribute to approximately 1.5% annual growth in the market.

Access The Detailed Genomic And Proteomic Tool Market Report Here

https://www.thebusinessresearchcompany.com/report/genomic-and-proteomic-tool-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR

What Are The Key Growth Opportunities In The Genomic And Proteomic Tool Market In 2030?

The most significant growth opportunities are anticipated in the reagents market, the instruments market, the software market, and the consumables market. Collectively, these segments are projected to contribute over \$25 billion in market value by 2030, driven by increasing adoption of next-generation sequencing and mass spectrometry technologies, expanding precision medicine initiatives, increasing investments in large-scale genomics and multi-omics research projects, growing demand for advanced bioinformatics and AI-based data analytics platforms, and continuous innovation in high-throughput and automated laboratory workflows. This momentum reflects the accelerating focus on enhancing molecular research accuracy, improving clinical diagnostics, and supporting targeted drug discovery and personalized therapeutic development, fuelling transformative growth across the broader

genomics and proteomics industry.

The reagents market is projected to grow by \$11 billion, the instruments market by \$8 billion, the software market by \$3 billion, and the consumables market by \$3 billion over the next five years from 2025 to 2030.

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/899740577>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.